1. Background {#sec123312}
=============

Galectin-3 (Gal-3) is a beta-galactoside-binding lectin that is associated with cardiac fibrosis in experimental studies ([@A28952R1], [@A28952R2]). In humans, Gal-3 has been shown to be a prognostic marker in acute ([@A28952R3]) as well as in chronic heart failure (CHF) ([@A28952R4]). Moreover, in patients with or without HF the presence of renal dysfunction is associated with higher serum levels of Gal-3 ([@A28952R5]). Higher levels of Gal-3 has been also found being ([@A28952R5]), and higher serum levels of Gal-3 are associated with renal fibrosis ([@A28952R6]) and a greater incidence of renal dysfunction ([@A28952R7]). Nevertheless, whether high Gal-3 levels are the cause or consequence of renal impairment in CHF has not been well established.

2. Objectives {#sec123313}
=============

In order to better clarify the relationship between Gal-3 levels and chronic kidney disease (CKD), we evaluated the relationship between Gal-3 serum levels and the urinary albumin/creatinine ratio (UACR) (i.e., a marker of alteration of size and/or charge selectivity of the glomerular basement membrane ([@A28952R8]) in a group of CHF outpatients).

3. Patients and Methods {#sec123314}
=======================

We enrolled outpatients with CHF who referred to the Heart Failure Unit of the University of Bari. At the time of enrolment, we included patients who were clinically stable for at least 30 days and who had been taking conventional medical and electrical therapy for at least 3 months. Patients with acute decompensated heart failure, acute worsening of kidney function, renal failure requiring dialysis or transplantation, and macroalbuminuria were excluded from the study. The protocol was approved by local ethical committee, and all patients gave their informed consent.

At the time of enrolment, all patients underwent a medical visit and electrocardiography. An echocardiographic evaluation was performed to evaluate left ventricular volumes and ejection fraction (LVEF), the presence of transmitral restrictive pattern, systolic peak of tricuspid annular plane excursion (TAPSE), central venous pressure (CVP), and pulmonary systolic artery pressure (PAPs), as previously described ([@A28952R9]). Blood samples were obtained to evaluate levels of amino-terminal brain natriuretic peptide (NT-proBNP; immunoassay Dade Behring, Eschborn, Germany), serum electrolytes (mEq/L), and serum creatinine (mg/dL). The glomerular filtration rate was calculated using the abbreviated CKD-EPI formula (GFR-EPI, mL/minute/1.73 m^2^). Gal-3 levels were measured from the plasma using an enzyme-linked immunosorbent assay (BG Medicine, Waltham, MA, USA). Normoalbuminuria, microalbuminuria, and macroalbuminuria were defined as a urinary albumin/creatinine ratio (UACR) of \< 30, 30 to 299, and ≥ 300 mg/g, respectively.

Continuous variables are expressed as mean ± standard deviation. Categorical variables are reported as frequencies and percentages. Univariate and stepwise multivariate logistic regression analyses were used to assess the association among studied variables and the presence of microalbuminuria. P \< 0.05 was considered statistically significant. The analyses were made using STATA software, Version 12 (StataCorp, College Station, Texas).

4. Results {#sec123315}
==========

Of 205 patients, 11 (6%) were excluded because of the presence of macroalbuminuria. The remaining 194 patients (81% male, 64 ± 13 years, New York Heart Association (NYHA) class 2.3 ± 0.6, LVEF 33% ± 9%) were evaluated. Seven (4%) patients among these had CHF with preserved ejection fraction, 37% had ischemic cardiomyopathy, 28% had diabetes mellitus, 54% had arterial hypertension, and 16% had atrial fibrillation. The mean estimated glomerular filtration rate (eGFR EPI) was 73 ± 25 mL/minute/1.73 m^2^, the mean NT proBNP value was 2030 ± 2881 pg/mL, and the mean Gal-3 level was 16.4 ± 7.1 ng/mL. Patients received conventional medical (angiotensin-converting-enzyme inhibitors and or angiotensin receptor blocker, 79%; betablockers, 96%; diuretics, 92%; aldosterone antagonist, 73%) or electrical therapy (86%, automatic cardioverter/defibrillator; 39%, cardiac resynchronization therapy device).

One-hundred thirty-three of the enrolled patients (69%) had normal levels of urinary albumin excretion (8 ± 8 mg/g), whereas 61 (31%) had microalbuminuria (105 ± 72 mg/g). [Table 1](#tbl31813){ref-type="table"} shows the mean values of the studied variables in patients with and those without microalbuminuria. The univariate logistic regression analysis showed that age, ischemic cardiomyopathy, diabetes, NYHA class, LVEF, PAPs, CVP, GFR-EPI, logarithm of NTproBNP, and Gal-3 levels were significantly associated with microalbuminuria.

###### Baseline Patients' Clinical and Therapeutic Characteristics According to the Presence or Absence of Microalbuminuria ^[a](#fn32610){ref-type="table-fn"}^

  Variables                                                              Microalbuminuria   Normoalbuminuria   Univariate Regression Analysis   
  ---------------------------------------------------------------------- ------------------ ------------------ -------------------------------- ----------
  **Number**                                                             61                 133                                                 
  **Age, y**                                                             68 ± 12            62 ± 13            1.04 (1.01 - 1.07)               0.004
  **Male gender** ^**[b](#fn32611){ref-type="table-fn"}**^               82                 79                 1.21 (0.56 - 2.63)               0.628
  **Ischemic cardiomyopathy** ^**[b](#fn32611){ref-type="table-fn"}**^   47                 32                 1.89 (1.02 - 3.53)               0.042
  **Diabetes** ^**[b](#fn32611){ref-type="table-fn"}**^                  39                 23                 2.23 (1.16 - 4.29)               \<0.001
  **Hypertension** ^**[b](#fn32611){ref-type="table-fn"}**^              52                 63                 1.03 (0.56 - 1.89)               0.927
  **BMI , kg/m^2^**                                                      27 ± 4             28 ± 5             0.94 (0.87 - 1.01)               0.089
  **Systolic pressure, mmHg**                                            120 ± 18           121 ± 16           0.99 (0.97 - 1.01)               0.443
  **NYHA class**                                                         2.5 ± 0.5          2.2 ± 0.6          1.99 (1.17 - 3.39)               0.011
  **LVEDV**                                                              166 ± 65           157 ± 59           1.00 (0.99 - 1.01)               0.353
  **LVEF** ^**[b](#fn32611){ref-type="table-fn"}**^                      31 ± 10            33 ± 9             0.96 (0.93 - 0.99)               0.042
  **TAPSE, mm**                                                          18 ± 4             19 ± 4             0.95 (0.89 - 1.02)               0.181
  **PAPs, mmHg**                                                         40 ± 18            32 ± 10            1.04 (1.02 - 1.07)               0.001
  **CVP, mmHg**                                                          6.3 ± 5.3          3.9 ± 3.0          1.15 (1.06 - 1.23)               \< 0.001
  **CVP \> 5, mmHg** ^**[b](#fn32611){ref-type="table-fn"}**^            26                 8                  4.37 (1.85 - 10.3)               \< 0.001
  **GFR-EPI,** **mL/minute/1.73 m** ^**2**^                              62 ± 24            78 ± 23            0.97 (0.96 - 0.98)               \< 0.001
  **NT-proBNP, pg/mL** ^**[c](#fn32612){ref-type="table-fn"}**^          3637 ± 4166        1298 ± 1584        1.92 (1.44 - 2.55)               \< 0.001
  **Gal-3, ng/mL**                                                       19.9 ± 8.8         14.6 ± 5.5         1.12 (1.07 - 1.18)               \< 0.001

^a^ Abbreviations: BMI, Body Mass Index; CVP, Central Venous Pressure; Gal-3, Galectin-3; GFR, Glomerular Filtration Rate; LVEDV, Left Ventricular End Diastolic Volume; LVEF, Left Ventricular Ejection Fraction; NT-proBNP, N-Terminal pro-Brain Natriuretic Peptide; PAPs, systolic peak of Pulmonary Arterial Pressure; TAPSE, peak of Tricuspid Annular Plane Systolic Excursion.

^b^ The values are presented as %.

^c^ Regression analyses performed after log-transformation.

A stepwise multivariate logistic regression analysis including age, diabetes, ischemic cardiomyopathy, NYHA class, LVEF, CVP \> 5 mm Hg, GFR-EPI, logNT-proBNP, and Gal 3, indicated that Gal-3 was the first variable that remained significantly associated with microalbuminuria (odds ratio \[OR\] 1.08, 95% confidence interval \[CI\]: 1.02 - 1.15, P = 0.012), followed by diabetes (OR 2.14; 95% CI: 1.00 - 4.57; P = 0.049) and PVC \> 5 mmHg (OR 2.80; 95% CI: 1.04 - 7.58; P = 0.042). No significant association was found with the remaining variables. To exclude the confounding effects of diabetes on our results, we analyzed the association between Gal-3 levels and microalbuminuria among 140 non-diabetic patients by using the above-mentioned multivariate regression model, after excluding diabetes as an independent variable. In this model, Gal-3 remained significantly associated with microalbuminuria (OR: 1.18; 95% CI: 1.09 - 1.27; P \< 0.001).

According to the ROC curve analysis, Gal-3 was significantly associated with microalbuminuria (AUC 0.69; 95% CI: 0.62 - 0.78). The best cutoff for Gal-3 (14.2 ng/mL) showed a sensitivity of 74% and a specificity of 56% in detecting the presence of microalbuminuria. However, as shown in the [figure 1](#fig23466){ref-type="fig"}, this cutoff could detect the subgroup of patients having a higher prevalence of microalbuminuria only among patients with GFR-EPI ≥ 60 mL/minute/1.73 m^2^, but not in those with GFR-EPI \< 60 mL/minute/1.73 m^2^.

![Prevalence of Microalbuminuria in Patients with GFR-EPI ≥ 60 mL/Minute/Minute × 1.73 m^2^ and in Those with GFR-EPI \< 60 mL/minute/1.73 m^2^ According to the Gal-3 Cutoff of 14.2 ng/mL\
Using Gal-3, the subgroup that showed significantly higher prevalence of microalbuminuria could be detected only in patients with relatively preserved renal function. Gal-3: galectin 3. GFR-EPI: estimated glomerular filtration rate by EPI formula.](cardiovascmed-05-01-28952-i001){#fig23466}

5. Discussion {#sec123316}
=============

To the best of our knowledge, our study findings are the first to show that Gal-3 serum levels are significantly and independently associated with microalbuminuria in CHF outpatients, thus suggesting a strong relationship between this new biomarker and CKD in this clinical setting.

Microalbuminuria plays a key role in the characterization of patients with CHF. Although estimation of GFR is considered the best overall measure of kidney function and is recommended for the routine evaluation in patients with CHF ([@A28952R10]), it presents a number of limitations ([@A28952R11]). As a consequence, other parameters have been proposed to better characterize renal function such as those providing integrative information on glomerular function or those reflecting tubular injury ([@A28952R11]). In this setting, microalbuminuria is a biomarker that can integrate the information of GFR and offers additive prognostic information ([@A28952R12], [@A28952R13]). In fact, in patients with preserved GFR, microalbuminuria could represent an early sign of renal damage, reflecting a reduced number of nephrons and hyperfiltration ([@A28952R13], [@A28952R14]). Moreover, microalbuminuria could be the result of the leakage of albumin through the endothelium and glomerular basement membrane that is strictly associated to endothelial dysfunction and inflammatory cytokine activation.

By demonstrating that Gal-3 is the first determinant significantly associated with Microalbuminuria, as indicated in the forward stepwise multivariate regression analysis, our results support a possible pathophysiological link between Gal-3 and CKD. This hypothesis is further strengthened by the fact that high Gal-3 levels were significantly associated with a greater prevalence of microalbuminuria in the presence of preserved GFR. On the basis of experimental studies, Gal-3 is considered a biomarker that can promote cardiac fibrosis ([@A28952R1], [@A28952R2]) and is associated with worse prognosis in patients with CHF. However, there are few data concerning the possible relationship between Gal-3 levels and renal dysfunction in patients with CHF. Experimental studies suggest that it could prevent chronic tubular injury and attenuate fibrosis in response to ischemic and nephrotoxic injury ([@A28952R15]), but could also promote fibrosis in cases of persistent tissue injury ([@A28952R16], [@A28952R17]). The possible involvement of Gal-3 in the genesis and progression of renal dysfunction has been also suggested by the results of Framingham Offspring Study, in which high levels of Gal-3 were associated with increased risk of GFR decline and incident CKD ([@A28952R7]). In CHF patients, the available data have only demonstrated an independent and negative correlation between Gal-3 levels and GFR ([@A28952R5]). However, it is unclear whether the increased Gal-3 serum levels reflect the consequence of CKD (reduced clearance and/or renal production) in patients with CHF or if these levels favor the onset and progression of CKD by their profibrotic effects ([@A28952R5]). The independent association between Gal-3 levels and microalbuminuria, particularly in patients with relatively preserved renal function, seems to support this last hypothesis. By promoting renal fibrosis, Gal-3 levels could mediate the progression of both renal and cardiac dysfunction, thus representing a biomarker that can better phenotyping of patients prone to progression of cardiorenal syndrome.

In our study, we did not evaluate the association between Gal-3 levels and biomarkers reflecting tubular injury that could further support our hypothesis. This is a limitation of our study. In conclusion, by demonstrating the independent association between Gal-3 levels and microalbuminuria in CHF outpatients, our study findings provide new useful data to better clarify the association between Gal-3 levels and CKD in these patients. Our results could also support the design of future studies aimed to prospectively evaluate the association among Gal-3 serum levels and the progression of renal dysfunction in CHF patients.
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